Alcon has signed two deals to expand its future drug portfolio, that includes gaining a licence for troubled GlaxoSmithKline product, cilomilast. The leading eye care company also announced a rise in third quarter global sales this week but investors’ attention was apparently focused on Alcon cutting its revenue outlook, causing a dramatic drop in the company’s share price.